Font Size: a A A

Clinical Observation Of Different Chemotherapy Drugs For Middle-advanced Cervical Carcinoma

Posted on:2018-10-07Degree:MasterType:Thesis
Country:ChinaCandidate:Y D XieFull Text:PDF
GTID:2334330536464165Subject:Surgery
Abstract/Summary:PDF Full Text Request
Objective: Through the analysis docetaxel combined with Nedaplatin or docetaxel combined with oxaliplatin into concurrent radiochemotherapy curative effect and adverse reaction for the treatment of locally advanced cervical carcinoma.Methods: Conducted the clinical data of patients from November 2014 to June 2016 in qinghai university affiliated hospital tumor of department of gynaecology treated the 60 cases of middle and advanced cervical carcinoma(Ⅱb-Ⅲb)were retrospectively analyzed.according to combination chemotherapy scheme by chemoradiation,collected data can be divided into different DN group(docetaxel+Nedaplatin group)and DA group(docetaxel + oxaliplatin group),DN group of 30 cases,DA group 30 cases.Comparison of two groups of patients with baseline information,short-term effects and toxicity.Results: Two groups of patients with baseline data including age,stage and so on compare differences had no statistical significance(P>0.05).DN group and DA group of efficient(RR)were 93.3% and 86.7% respectively,which DN group of complete remission(CR)rate(80.0%)compared with DA group(70.0%),differences were no significant(P>0.05).On hematology toxicity;The chance of hypoleukmia,thrombopenia,anemia of DN group is significantly higher than the DA group,difference was statistically significant(P<0.05),but it mainly reflects inⅠandⅡlevel.On non-hematological toxicity,the chance of peripheral neuropathy of DN group was obviously lower than the DA group(P<0.05);Gastrointestinal adverse reaction,hepar and renal functional lesion differences and hair loss were no significant between two groups(P>0.05).Radiation enteritis and radiation cystitis differences were no significant between two groups(P>0.05).Conclusion : For the treatment of middle and advanced cervical cancer,docetaxel combined with Nedaplatin or docetaxel combined with oxaliplatin have similar efficacy.In the adverse reactions,the chance of hypoleukmia,thrombopenia and hair loss of DN group is significantly higher than the DA group(P<0.05).the chance of peripheral neuropathy of DN group was obviously lower than the DA group(P<0.05).
Keywords/Search Tags:Cervical carcinoma, Concurrent chemoradiotherapy, Curative, effect Adverse reactions
PDF Full Text Request
Related items
Curative Effect Of Different Chemotherapy Drugs On Synchronous Chemoradiotherapy Of Cervical Squamous Cell Carcinoma
Retrospective Analysis Of Curative Effect And Prognostic Factors Of Radical Concurrent Chemoradiotherapy For Local Advanced Cervical Cancer
Short-Term Curative Effect Of Concurrent Chemoradiotherapy With Helical Tomotherapy And Intensity-Modulated Radiotherapy For Early Cervical Cancer After Surgery
Preliminary Study On Micrornas Level And Clinicopathological Factors To Predict The Effect Of Concurrent Chemoradiotherapy In Advanced Squamous Cervical Carcinoma
Curative Effect Of Concurrent Chemoradiotherapy On Therapying Patients With Metaphase And Advanced Stage Of Squamous Cell Cervical Carcinoma And Tumor Diameter And Imaging Lymph Node Status As Its Prognostic
Comparison Of Efficacy And Adverse Reactions Of Two Cisplatin-Based Concurrent Chemoradiotherapy Regimens In The Treatment Of Esophageal Squamous Cell Carcinoma
A Comparative Proteomic Study Of Cervical Carcinoma Tissues With Different Concurrent Chemoradiotherapy Sensitivity
Part â… :Preliminary Study Of Serum MicroRNAs Related To The Sensitivity To Concurrent Chemoradiotherapy In Advanced Cervical Squamous Cell Carcinoma Part â…¡:Clinical Analysis Of 32 Cases With Neuroendocrine Carcinoma Of The Uterine Cervix In Early-Stage
Radiomics Study On The Prediction Of Curative Effect Of Radical Concurrent Chemoradiotherapy In Cervical Cancer
10 Comparison Of The Efficacy Of Salvage Radiotherapy And Concurrent Chemoradiotherapy In Patients With Local Recurrence Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy